PARP1 and small cell lung carcinoma: SLFN11 has been identified as critical for SCLC cell line and patient-derived xenograft (PDX) response to chemotherapy [34,35], as well as a potential biomarker for PARP inhibitor response using unbiased screens in SCLC cell lines and PDXs [33,35].